Altogether our studies support a putative tumor proliferation inhibition role of PHF14 in some neurocytomas, and suggest that Sunitinib could be a feasible treatment choice for some patients with residual/recurrent neurocytoma. This evidence concerns the gene PHF14 and central neurocytoma.